Pharmacists identify clinically important medication risks every day. The unresolved question is what happens after the message leaves the pharmacy and before the prescription changes.
Audience: Practicing Pharmacists
Countries: USA, UK, Canada, France, Italy, Germany
SGID: 8799556
– Hero finding
Quick Read — Key Findings
Explore where the communication loop slows, why workarounds become routine, and which conditions make prescribing decisions change.
// The backstory
Pharmacists routinely detect interactions, contraindications, dosing concerns, legal issues, and patient-specific risks. The safety value of that expertise depends on whether the right prescriber can be reached, the concern is understood, and the action is completed in time.
WHO’s Medication Without Harm initiative frames medication safety as a system priority. FIP guidance positions pharmacists as essential partners in collaborative care, while AHRQ closed-loop communication requires confirmation that a message is received, understood, and completed.
WHO describes adherence as a multidimensional behaviour, while AHRQ recommends teach-back to confirm that information has been explained clearly. NICE guidance also asks clinicians to explore beliefs, concerns, preferences, and non-verbal cues rather than assuming that agreement equals readiness.
Sources: World Health Organization, Medication Without Harm; International Pharmaceutical Federation, Collaborative Practice; AHRQ, Closed-Loop Communication.
We asked practising pharmacists in the United States, United Kingdom, Canada, France, Italy, and Germany what prompts outreach, what makes recommendations influential, and where communication loses momentum.
Finding 1
78.3% initiate communication very frequently or frequently. The main triggers are drug interactions, contraindications, and concerns about dose, duration, or regimen complexity.
What the pattern means: Pharmacists are not contacting prescribers only at the edge of an emergency. They are functioning as a routine clinical checkpoint before medication risk reaches the patient.
Finding 2
A safety concern supported by clear clinical risk is the communication most likely to influence prescribing at 57.0%. Dosing optimization and therapeutic alternatives follow, while patient-behaviour insight has limited reported influence.
The insight: The pharmacist’s voice is strongest when the risk is concrete, immediate, and easy to translate into an action. This may undervalue earlier input about adherence, tolerability, or preventive optimization, even when those issues shape long-term outcomes.
Finding 3
43.0% report prompt action, while 37.3% say the concern is acknowledged but delayed or dependent on further validation. The gap is not mainly rejection. It is the time between recognition and completion.
Why this matters: A delayed response can leave the patient waiting, delay treatment, or force repeated calls. Medication safety depends on a completed action, not simply a message sent.
Finding 4
Difficulty reaching the prescriber and delayed or absent responses account for 83.4% of reported breakdowns. This points to infrastructure and availability, not a lack of pharmacist willingness to communicate.
What may be behind it: Prescribers and pharmacists work across different systems, schedules, and priorities. Without a shared urgent pathway and a response expectation, the pharmacist may need to repeat the same message through multiple channels.
Finding 5
53.1% resolve issues informally very frequently or frequently, and another 39.6% do so occasionally when appropriate and within scope.
The deeper pattern: A workaround can be an appropriate use of professional scope. Repeated workarounds can also be a system signal: the official communication route may be slower than the clinical problem allows.
Finding 6
An established working relationship and a clear evidence-based rationale together account for 67.7% of what most improves action. Direct and timely communication channels add another 21.9%.
What the pattern means: The same recommendation can produce a different result depending on trust, access, and how clearly the next step is framed. Effective collaboration is therefore both a clinical skill and a system design issue.
Context: AHRQ closed-loop communication confirms that a message is received, understood, and completed. FIP collaborative-practice guidance emphasizes integrated teamwork and the pharmacist’s contribution to safer medication use.
Use direct contact for time-critical risk and reliable electronic channels for issues that can wait, with clear acknowledgement expectations for both.
State the patient-specific risk, relevant evidence, recommended action, and a practical alternative in a concise structured message.
Confirm who is acting, what decision is made, and whether the prescription or monitoring plan changes. Repeated unresolved concerns should trigger escalation rather than repeated informal workarounds.
//People Also Ask
Direct answers to the questions professionals most often search around this topic.
Direct answers to the questions healthcare professionals are most likely to ask about these findings.
